Interpace Biosciences Reports Robust Q4 and Full Year 2025 Results, Signals Strong Outlook for 2026
Key Highlights for Investors
- Q4 and FY 2025 Revenue: \$9.2 million and \$38.7 million, respectively
- Q4 and FY 2025 Income from Continuing Operations: \$22.8 million and \$25.0 million, respectively, significantly boosted by a one-time, non-cash tax-related accounting adjustment
- Thyroid Test Volume and Revenue Growth: Thyroid test volume increased 11% in Q4 and 13% for the year; thyroid revenue grew 14% in Q4 and 21% for the full year
- Transition to Thyroid-Only Business: Completed exit from PancraGEN business, now a focused thyroid diagnostics company
- Operational Improvements: DSO (Days Sales Outstanding) down 19%, turnaround time down 20%, average revenue per test up 5%, average volume per account up 6%, number of accounts up 9%, and recurring account conversion up 10%
- Debt Paid Off: Company fully paid off all debt in Q4 2025; cash balance increased by \$4.3 million year-over-year
- 2026 Outlook: Company reaffirms guidance for approximately 16% year-over-year thyroid revenue growth
Detailed Analysis and Key Developments
Interpace Biosciences, Inc. (OTCQX: IDXG) reported its financial and operational results for the fourth quarter and full year ended December 31, 2025, marking a pivotal year for the company as it transitions to a streamlined, thyroid-only diagnostics business.
Financial Performance Overview
-
Revenue: Q4 2025 revenue was \$9.2 million, representing a 26% decrease from \$12.4 million in Q4 2024 due to the discontinuation of the PancraGEN product line, but a 20% increase over the pro forma Q4 2024 thyroid-only results. Full year 2025 revenue was \$38.7 million, down 18% compared to \$46.9 million in 2024, but up 17% over 2024 pro forma figures.
-
Profitability: The company reported Q4 income from continuing operations of \$22.8 million and full-year income from continuing operations of \$25.0 million. These figures were substantially aided by a one-time, non-cash tax-related accounting adjustment related to the release of a deferred tax valuation allowance.
-
Adjusted EBITDA: Adjusted EBITDA for Q4 was \$1.7 million (versus \$2.2 million in Q4 2024 and \$0.2 million pro forma), and for the full year was \$5.4 million (versus \$8.7 million in 2024 and \$2.3 million pro forma).
-
Cash Flow and Balance Sheet: 2025 cash collections were \$41.7 million, slightly down from \$43.6 million in 2024. The company ended 2025 with \$2.5 million in cash and cash equivalents, up from \$1.5 million at the end of 2024. Interpace also strengthened its balance sheet by paying off all debt and reducing total liabilities to \$11.5 million from \$17.0 million year-over-year.
-
Stockholder Equity: Shareholders’ equity rose dramatically to \$22.4 million at year-end 2025 from a deficit of \$2.2 million at the end of 2024, primarily due to the accounting adjustment and improved profitability.
Operational Highlights
- Thyroid test volumes and revenue grew robustly, with thyroid revenue up 14% in Q4 and 21% for the year, supported by volume increases of 11% and 13%, respectively.
- Average thyroid revenue per test increased 5% over the prior year.
- Operational efficiency improved as days sales outstanding decreased by 19% and turnaround time dropped by 20%.
- Average volume per account increased 6%, total accounts rose by 9%, and the percentage of new accounts converted to recurring increased by 10%.
Strategic and Business Updates
-
Thyroid Diagnostics Focus: Following the discontinuation of PancraGEN in May 2025, Interpace is now an exclusively thyroid-focused diagnostics company, leveraging its ThyGeNEXT® and ThyraMIR® v2 platforms.
-
Investments in Technology: The company continued investing in laboratory automation and AI to drive operational efficiency as part of its digital strategy.
-
Growth Initiatives: The company aims to accelerate execution in 2026, focusing on deeper penetration within existing accounts, new account growth, and productivity gains.
Shareholder-Relevant, Potentially Price-Sensitive Information
-
One-Time, Non-Cash Tax Adjustment: The significant jump in net income and income from continuing operations was largely the result of a one-time, non-cash release of a deferred tax valuation allowance, not from core operating performance. This should be carefully considered by shareholders as it may not recur and could impact future comparability of earnings.
-
Debt Elimination and Improved Liquidity: The company’s full repayment of debt and increase in liquidity strengthens its financial position, reducing interest expense and risk in a rising rate environment.
-
2026 Guidance: Management reaffirmed its outlook for 16% year-over-year thyroid revenue growth, signaling continued confidence in its focused strategy and market momentum.
-
Transition-Driven Comparability: With the full exit from PancraGEN, all ongoing results now reflect a streamlined, thyroid-only business, which may lead to improved operational focus and margin profile.
Financial Statements (Selected Figures)
-
Q4 2025 Net Income Attributable to Common Stockholders: \$22.7 million (\$5.14 basic EPS; \$0.82 diluted EPS)
-
FY 2025 Net Income Attributable to Common Stockholders: \$24.6 million (\$5.65 basic EPS; \$0.90 diluted EPS)
-
Cash and Cash Equivalents at Year-End: \$2.5 million (up from \$1.5 million prior year)
-
Total Assets: \$33.8 million (up from \$14.8 million prior year)
-
Total Liabilities: \$11.5 million (down from \$17.0 million prior year)
Outlook for 2026
With a sharpened focus on thyroid diagnostics, improved operational efficiency, and a much stronger balance sheet, Interpace is well-positioned to deliver on its guidance for 16% thyroid revenue growth in 2026. The company’s combination of molecular (ThyGeNEXT®) and microRNA (ThyraMIR® v2) diagnostics platforms is expected to drive deeper market adoption and enhance value for physicians and patients.
Risks and Considerations
-
The exceptional 2025 net income was significantly augmented by a one-time, non-cash tax benefit. Investors should not expect this to repeat in future periods.
-
Revenue and profit growth in coming years will depend on execution in the core thyroid business, successful adoption of technology improvements, and continued expansion of the account base.
-
As always, reimbursement and payer risk, as well as execution on growth initiatives, remain important factors for future performance.
About Interpace Biosciences
Interpace Biosciences is a leader in personalized medicine, specializing in molecular diagnostics for thyroid cancer. The company’s flagship tests, ThyGeNEXT® and ThyraMIR® v2, provide advanced genetic and microRNA profiling to enable more accurate diagnosis and management of thyroid nodules.
Contact Information
Disclaimer
This article is for informational purposes only. It contains forward-looking statements which are subject to risks and uncertainties. Actual results may differ materially from those anticipated. Readers should review the company’s filings with the SEC for a full discussion of risks and uncertainties. This article does not constitute investment advice or a recommendation to buy or sell any securities.
View INTERPACE BIOSCIENCES, INC. Historical chart here
